It is estimated that 40% to 100% of immunocompetent adults are cytomegalovirus (CMV) seropositive globally \[[@CIT0001]\]. In Canada, the seroprevalence ranges between 60% and 80% \[[@CIT0002]\]. Most primary infections occur in childhood and are subclinical or present with nonspecific symptoms. Cytomegalovirus subsequently remains latent in monocytes and macrophages \[[@CIT0003]\]. This state of latency allows CMV to reactivate when host defenses become compromised, such as in critical illness. Cytomegalovirus reactivation in critically ill patients is well recognized with as high as 71% incidence \[[@CIT0004]\]. The consequences of CMV reactivation in immunocompromised patient populations, such as those with solid organ transplants, have been well described \[[@CIT0005]\]. However, the clinical significance in immunocompetent patients remains controversial. Some postulate viral pathogenesis. Others have suggested that CMV reactivation is only a marker of illness severity \[[@CIT0004]\].

Since the 1990s, several studies have investigated the association between CMV reactivation and outcomes in critically ill patients. In 1990, Domart et al \[[@CIT0006]\] examined patients with mediastinitis after cardiac surgery who were CMV infected, defined by blood and/or urine viral cultures. They showed a significant increase in mortality and hospital length of stay (LOS) compared with CMV-uninfected patients. Thereafter, other studies have also reported increased mortality \[[@CIT0007], [@CIT0008]\], increased duration of mechanical ventilation \[[@CIT0009], [@CIT0010]\], increased length of intensive care unit (ICU) stay \[[@CIT0011], [@CIT0012]\], and increased incidence of nosocomial infections \[[@CIT0013]\]. Contrasting these data, other authors \[[@CIT0014], [@CIT0015]\] failed to demonstrate a difference in mortality in patients with CMV DNAemia.

With a growing number of studies examining the association between CMV reactivation and ICU outcomes, as well as discrepancies in the available data, systematic reviews and meta-analyses have been previously undertaken. In 2009, Osawa et al \[[@CIT0016]\] conducted the first systematic review on the subject, including 13 studies. Four studies reported data on duration of mechanical ventilation, all of which showed longer durations of ventilation in patients with CMV reactivation; however, these data were not meta-analyzed. All but 2 of the included studies reporting death showed no association between CMV reactivation and mortality \[[@CIT0016]\]. In contrast, Kalil et al \[[@CIT0017]\] published a meta-analysis including 8 studies and 633 patients showing a 2-fold increase in the odds ratio of death with CMV infection. However, other clinical outcomes were not examined. These authors updated their results after Heininger et al \[[@CIT0014]\]. Given their discordant results, however, the association between CMV infection and mortality remained significant \[[@CIT0018]\]. Finally, Coisel et al \[[@CIT0019]\] performed a prospective outcomes study of CMV-infected mechanically ventilated patients in which they included a meta-analysis demonstrating increased mortality in patients with CMV antigenemia. Since the publication of this last meta-analysis, at least 4 additional studies have been published on this topic with varying results \[[@CIT0015], [@CIT0020]\].

Considering the availability of new evidence and the absence of meta-analyses examining important outcomes such as duration of mechanical ventilation, ICU LOS, or incidence of nosocomial infection, we conducted this systematic review and meta-analysis to explore the association between CMV reactivation and clinical outcomes in immunocompetent critically ill patients.

METHODS {#s1}
=======

The protocol of this systematic review has been previously published \[[@CIT0023]\] and was registered with the International Prospective Register of Systematic Reviews (PROSPERO; CRD-42016035446).

Objectives {#s2}
----------

The aim of our systematic review was to explore the association between CMV reactivation (defined by positive pp65 CMV antigen testing, CMV quantitative nucleic acid testing \[NAT\], or viral culture in either blood or bronchoalveolar lavage) and patient-centered outcomes (including mortality, duration of mechanical ventilation, nosocomial infections, and receipt of renal replacement therapy \[RRT\]) or health services utilization (ICU LOS, hospital LOS) in immunocompetent critically ill patients.

Data Searches {#s3}
-------------

In brief, the search strategy was developed in consultation with an expert librarian (R.F.). Electronic databases including Ovid MEDLINE, Ovid EMBASE, and the Cochrane Library (including the Cochrane Database of Systematic Reviews and the Cochrane Central Register of Controlled Trials \[CENTRAL\]) were searched for 3 broad domains: cytomegalovirus, intensive care unit, and sepsis. Search results were restricted to papers published after 1990 and in English or French languages. Relevant conference proceedings (see protocol for details) from the past 2 years and [www.clinicaltrials.gov](www.clinicaltrials.gov) were also screened. Supplementary Appendix 1 presents the complete search strategy.

Study Selection {#s4}
---------------

We included randomized trials, observational studies (either retrospective or prospective), or case-control studies that reported on CMV reactivation in immunocompetent adults ≥18 years old (ie, we specifically excluded solid organ or bone marrow transplant patients, those with advanced human immunodeficiency virus/acquired immune deficiency syndrome or those receiving cytotoxic therapies) and at least 1 patient-centered outcome (mortality, duration of mechanical ventilation, nosocomial infections, RRT) or measure of health resource utilization (ICU and hospital lengths of stay). Two authors (P.L. and J.C.) identified potentially eligible articles after independent review. Any disagreements were resolved through discussion and/or arbitration by the senior author (W.I.S.).

Data Extraction {#s5}
---------------

Data were abstracted from relevant studies by the same 2 authors (P.L. and J.C.) using a standardized electronic data collection form. Additional or missing data, where relevant, were requested from primary authors of included studies on up to 3 attempts. Extracted data included publication-related information, design and quality assessment, inclusion and exclusion criteria, and the method of CMV detection. Demographic and clinical characteristics of the study populations, as well as patient-related and health resource use outcomes, were also included. Supplementary Appendix 2 provides a complete list of all data variables collected. Study methodological quality was rated using the Newcastle-Ottawa Scale \[[@CIT0024]\] for observational and case-control studies.

Outcomes {#s6}
--------

Our primary outcome was ICU mortality. Secondary outcomes included overall mortality (a combination of 28-day, 30-day, hospital, and long-term mortality), duration of mechanical ventilation, nosocomial infections, need for RRT, vasopressor days, and ICU and hospital lengths of stay.

Analysis {#s7}
--------

Pooled effect estimates of the association between CMV reactivation and patient-centered outcomes and health service use were calculated. We assessed and quantified statistical heterogeneity for each pooled estimate using the I^2^ statistic. Pooled analyses were performed using random effects models (Mantel-Haenszel method) and reported as odds ratios (ORs) with 95% confidence intervals (CIs) for categorical variables and weighted mean differences with 95% CIs for continuous variables. Sensitivity analyses were explored for the primary outcome of ICU mortality including the following: by year of study (before or after 2005), study sample size (large versus small based on median split of included studies), study quality (Newcastle-Ottawa score ≥6 \[high quality\] versus \<6 \[low quality\]), diagnostic methodology (molecular diagnostics versus antigen and/or culture methods), disease severity (high \[APACHE II ≥22, SOFA ≥5, or SAPS II ≥33\] versus low), and in a subgroup of patients requiring mechanical ventilation. Publication bias was assessed by visualization of funnel plots. All analyses were performed using Review Manager (RevMan), version 5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).

RESULTS {#s8}
=======

Our search strategy yielded 1945 original titles and abstracts after removal of duplicates. Fifty-two full-text articles were reviewed for eligibility; 21 studies \[[@CIT0006], [@CIT0007], [@CIT0009], [@CIT0019], [@CIT0020], [@CIT0022], [@CIT0025]\] and 1 abstract \[[@CIT0034]\] with a total of 2199 patients were included in our meta-analysis (Supplementary Appendix 3). A summary of studies reviewed in full text, but not fulfilling eligibility, is shown in Supplementary Appendix 4.

[Table 1](#T1){ref-type="table"} and Supplementary Appendix 5 present the main characteristics of our included studies. Patient populations by study were quite variable; 3 studies included only surgical patients \[[@CIT0006], [@CIT0009], [@CIT0022]\], 5 included patients with sepsis \[[@CIT0011], [@CIT0012], [@CIT0020], [@CIT0025], [@CIT0026]\], 2 included burn patients \[[@CIT0007], [@CIT0028]\], 6 included only mechanically ventilated patients \[[@CIT0010], [@CIT0015], [@CIT0019], [@CIT0029], [@CIT0031], [@CIT0033]\], 1 included acute respiratory distress syndrome (ARDS) patients \[[@CIT0033]\], and 6 used various inclusion criteria \[[@CIT0013], [@CIT0014], [@CIT0027], [@CIT0030], [@CIT0032], [@CIT0034]\]. Studies published after 2006 were more likely to examine specific patient populations compared with earlier studies.

###### 

Included Studies

  -------------------------------------------------------------------------------------------------------------------------------------------
  **Study**                   **Design**                  **Patient Population**                                **Method of CMV Detection**
  --------------------------- --------------------------- ----------------------------------------------------- -----------------------------
  Domart et al \[6\]          Observational prospective   Post-op cardiac surgery                               Culture

  Cook et al \[12\]           Case control                Sepsis                                                Culture

  Kutza et al \[25\]          Observational prospective   Sepsis                                                PCR or pp65

  Heininger et al \[11\]      Observational prospective   Sepsis                                                PCR or Culture

  Cook et al \[9\]            Observational prospective   Postsurgical                                          Culture

  Jaber et al \[13\]          Case control                General ICU                                           pp65

  Muller et al \[26\]         Observational prospective   Septic shock                                          pp65

  Limaye et al \[7\]          Observational prospective   Burns with TBSA \>40%                                 PCR

  Ziemann et al \[27\]        Case control                General ICU \>14 days                                 PCR

  Chiche et al \[10\]         Observational prospective   Mechanical ventilation                                pp65 or culture or biopsy

  Bordes et al \[28\]         Observational prospective   Burns with\                                           PCR
                                                          TBSA \>15%                                            

  Heininger et al \[14\]      Observational prospective   SAPS \>41, CMV IgG^+^                                 PCR or culture

  Chiche et al \[29\]         Case control                ICU admission, CMV IgG^+^, mechanical ventilation     pp65

  Coisel et al \[19\]         Observational prospective   Mechanical ventilation, suspected pneumonia           PCR or pp65

  Al-Musawi 2014^a^ \[34\]    Case control                Thrombocytopenia                                      PCR

  Bravo et al \[30\]          Observational prospective   ICU \>5 days, CMV IgG^+^                              PCR

  Osman et al \[31\]          Observational prospective   Mechanical ventilation                                PCR

  Walton et al \[20\]         Observational prospective   General ICU                                           PCR

  Frantzeskaki et al \[15\]   Observational prospective   Mechanical ventilation, CMV IgG^+^                    PCR

  Lopez Roa et al \[22\]      Observational prospective   Post-op cardiac surgery, ICU \>72 hours               PCR

  Ong 2016 \[33\]             Observational prospective   ARDS, mechanical ventilation \>96 hours, CMV IgG^+^   PCR

  Osawa 2016 \[32\]           Observational prospective   BSI                                                   PCR
  -------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ARDS, acute respiratory distress syndrome; BSI, bloodstream infection; CMV, cytomegalovirus; ICU, intensive care unit; Ig, immunoglobulin; op, operative; PCR, polymerase chain reaction; SAPS, simplified acute physiology score; TBSA, total body surface area.

^a^Abstract only.

Eleven studies included only CMV (immunoglobulin G) seropositive patients \[[@CIT0007], [@CIT0011], [@CIT0014], [@CIT0015], [@CIT0020], [@CIT0026], [@CIT0028], [@CIT0032], [@CIT0033]\]. No randomized control trials met eligibility. Seventeen studies were observational \[[@CIT0006], [@CIT0007], [@CIT0009], [@CIT0014], [@CIT0015], [@CIT0019], [@CIT0020], [@CIT0022], [@CIT0025], [@CIT0026], [@CIT0028], [@CIT0030]\] and 5 were case controls \[[@CIT0012], [@CIT0013], [@CIT0027], [@CIT0029], [@CIT0034]\]. Eleven studies used NAT (namely, polymerase chain reaction \[PCR\] testing) alone \[[@CIT0007], [@CIT0015], [@CIT0020], [@CIT0022], [@CIT0027], [@CIT0028], [@CIT0030]\], whereas 5 used more than 1 method for CMV detection \[[@CIT0010], [@CIT0011], [@CIT0014], [@CIT0019], [@CIT0025]\]. We included all types of ICU patients (ie, medical, general surgical, cardiac surgical, and burns). Unfortunately, few clinical characteristics, such as comorbid diseases or illness severity scoring, were reported ([Table 2](#T2){ref-type="table"}). The prevalence of CMV reactivation ranged from 9% to 71% (Supplementary Table 3). Supplementary Appendices 6 and 7 present our quality assessment of the included studies.

###### 

Clinical Characteristics of Included Study Populations

  **CMV Reactivation**            **No CMV Reactivation**                                                                                                                                                      
  ------------------------------- ------------------------- ----- ----- ------------------- ---------------- ---------------- ----- ---- ----- ----- ----- ------------------ --------------- ---------------- -----
  Domart et al \[6\]              29                        59    69    15 (8)^b^           n/a              n/a              36    25   86    56    12    14 (7)^b^          n/a             n/a              25
  Cook et al (1)^d^ \[12\]        20                        63    60    13 (1)^b^           n/a              n/a              n/a   10   122   58    n/a   14 (1)^b^          n/a             n/a              n/a
  Kutza et al \[25\]              11                        58    100   n/a                 n/a              n/a              n/a   32   23    58    70    n/a                n/a             n/a              n/a
  Heininger et al (1)d \[11\]     20                        69    55    n/a                 n/a              42 (9)^b^        100   36   36    67    66    n/a                n/a             42 (16)^a^       100
  Cook et al (2)^e^ \[9\]         10                        69    n/a   13 (n/a)            n/a              n/a              100   9    94    58    n/a   13 (n/a)           n/a             n/a              70
  Jaber et al \[13\]              40                        62    68    n/a                 n/a              51 (16)^b^       n/a   51   40    61    70    n/a                n/a             49 (16)^a^       n/a
  Muller et al \[26\]             8                         66    63    n/a                 10 (7--13)^a^    n/a              100   32   17    60    59    n/a                10 (7--16)^a^   n/a              100
  Limaye et al \[7\]              39                        n/a   n/a   n/a                 n/a              n/a              100   33   81    n/a   n/a   n/a                n/a             n/a              100
  Ziemann et al \[27\]            35                        68    66    n/a                 n/a              n/a              65    35   64    65    67    n/a                n/a             n/a              28
  Chiche et al (1)^d^ \[10\]      39                        68    69    n/a                 8 (7--11)^a^     49 (16)^b^       90    19   203   62    65    n/a                9 (6--11)^a^    48 (17)^b^       72
  Bordes et al \[28\]             15                        63    n/a   n/a                 n/a              n/a              100   71   6     49    n/a   n/a                n/a             n/a              100
  Heininger et al (2)^e^ \[14\]   35                        68    77    n/a                 8 (6--10)^a^     43 (33--47)^a^   100   41   51    69    78    n/a                9 (7--12)^a^    44 (37--53)^a^   100
  Chiche et al (2)^e^ \[29\]      15                        67    60    n/a                 10 (6--11)^a^    49 (30--73)^a^   100   50   15    72    60    n/a                8 (4--9)^a^     47 (36--62)^a^   100
  Coisel et al \[19\]             21                        69    64    n/a                 7 (5--9)^a^      40 (31--53)^a^   95    34   40    59    60    n/a                8 (6--10)^a^    44 (31--55)^a^   76
  Al-Musawi \[34\]^f^             n/a                       52    77    n/a                 27 (14--48)^a^   n/a              62    52   n/a   47    66    n/a                21 (2--34)^a^   n/a              55
  Bravo et al \[30\]              36                        67    66    22.5 (11--34)^a^    n/a              n/a              100   46   42    67    74    19 (10--39) ^a^    n/a             n/a              100
  Osman et al \[31\]              35                        n/a   n/a   n/a                 n/a              n/a              n/a   69   16    n/a   n/a   n/a                n/a             n/a              n/a
  Walton et al \[20\]             86                        n/a   n/a   n/a                 n/a              n/a              100   24   270   n/a   n/a   n/a                n/a             n/a              100
  Frantzeskaki et al \[15\]       11                        60    73    20 (4--27)^a^       10 (5)^b^        n/a              100   14   69    62    62    20 (11--43)^a^     8 (3)^b^        n/a              100
  Lopez Roa et al \[22\]          16                        n/a   n/a   n/a                 n/a              n/a              100   33   32    n/a   n/a   n/a                n/a             n/a              n/a
  Ong et al \[33\]                74                        64    59    91 (71--113)^a,c^   n/a              n/a              100   27   197   64    61    76 (62--99)^a,c^   n/a             n/a              100
  Osawa et al \[32\]              20                        67    60    28 (24--31)^a^      n/a              n/a              100   20   80    61    72    24 (19--28)^a^     n/a             n/a              100

Abbreviations: APACHE, acute physiology and chronic health evaluation; CMV, cytomegalovirus; Ig, immunoglobulin; IQR, interquartile range; n/a, nonapplicable; SAPS, simplified acute physiology score; SD, standard deviation; SOFA, sequential organ failure assessment.

^a^Median (IQR).

^b^Mean (SD).

^c^APACHE IV score used.

^d^Designed the oldest of the two articles from this author included in the systematic review.

^e^Designed the most recent of the two articles from this author included in the systematic review.

^f^This reference is an abstract.

Mortality {#s9}
---------

In our primary analysis, CMV reactivation was associated with a 2.5-fold increase in ICU mortality with low heterogeneity (10 studies, n = 970 patients, OR = 2.55, 95% CI = 1.87--3.47; *P* \< .001, I^2^ = 0%) ([Figure 1](#F1){ref-type="fig"}). Subgroup analyses yielded similar results ([Figure 2](#F2){ref-type="fig"}). All studies were high quality (Ottawa-Newcastle scale ≥6) so we could not stratify by study quality. Visual assessment of funnel plots did not show evidence of publication bias (Supplementary Appendix 8).

![Association between cytomegalovirus (CMV) reactivation and intensive care unit mortality. Abbreviation: CI, confidence interval.](ofx02901){#F1}

![Subgroup analyses for intensive care unitICU mortality](ofx02902){#F2}

Secondary Outcomes {#s10}
------------------

### Patient-Related Outcomes {#s11}

Cytomegalovirus reactivation was associated with increased overall mortality (14 studies, n = 1814 patients, OR = 2.02, 95% CI = 1.60--2.56; P \< .001, I2 = 8%) ([Figure 3](#F3){ref-type="fig"}). Subgroup analyses yielded similar results (Supplementary Appendix 9). Again, stratification by study quality was not possible because all studies were graded as high quality.

![Association between cytomegalovirus (CMV) reactivation and overall mortality in immunocompetent critically ill patients. Abbreviation: PCR, polymerase chain reaction.](ofx02903){#F3}

Cytomegalovirus reactivation was also associated with increased duration of mechanical ventilation (7 studies, n = 683 patients, mean difference 6.60 days, 95% CI = 3.09--10.12; *P* = .0002, I^2^ = 79%) ([Figure 4A](#F4){ref-type="fig"}). Only 7 studies \[[@CIT0013], [@CIT0019], [@CIT0027], [@CIT0028], [@CIT0031]\] could be included because other studies were lacking any data on mechanical ventilation \[[@CIT0006], [@CIT0007], [@CIT0011], [@CIT0012], [@CIT0015], [@CIT0020], [@CIT0022], [@CIT0025], [@CIT0030], [@CIT0034]\] or could not be obtained despite contacting the authors \[[@CIT0009], [@CIT0010], [@CIT0014], [@CIT0026], [@CIT0029]\]. Of note, the 5 studies reporting data on ventilation but missing means and/or standard deviations all demonstrated statistically significant longer durations of mechanical ventilation in patients with CMV reactivation (Cook et al \[[@CIT0009]\] mean 33 vs 13 days, Chiche et al \[[@CIT0010]\] median 27 vs 10 days, Heininger et al \[[@CIT0014]\] median 22 vs 8 days, von Müller et al \[[@CIT0026]\] median 39 vs 16 days, and Chiche et al \[[@CIT0029]\] median 24 vs 8 days, in patients with and without CMV reactivation, respectively).

![(A) Association between cytomegalovirus (CMV) reactivation and mechanical ventilation duration in immunocompetent critically ill patients. (B) Association between CMV reactivation and nosocomial infection in immunocompetent critically ill patients. (C) Association between CMV reactivation and need for renal replacement therapy in immunocompetent critically ill patients. (D) Association between CMV reactivation and intensive care unit length of stay in immunocompetent critically ill patients. Abbreviations: CI, confidence interval; SD, standard deviation.](ofx02904){#F4}

Finally, CMV reactivation was associated with an increase in incidence of nosocomial infections (7 studies, n = 659 patients, OR = 3.20, 95% CI = 2.05--4.98; *P* \< .001, I^2^ = 0%) ([Figure 4B](#F4){ref-type="fig"}) and need for RRT (3 studies, n = 343 patients, OR = 2.37, 95% CI = 1.31--4.31; *P* = .005, I^2^ = 0%) ([Figure 4C](#F4){ref-type="fig"}). The most common nosocomial infections were ventilator-acquired pneumonia, bacteremia, and fungal infections.

### Health Resource Utilization {#s12}

Intensive care unit LOS was increased in patients with CMV reactivation (9 studies, n = 973 patients, mean difference 8.18 days, 95% CI = 6.14--10.22; *P* \< .001, I^2^ = 65%) ([Figure 4D](#F4){ref-type="fig"}). Again, 7 studies \[[@CIT0009], [@CIT0014], [@CIT0026], [@CIT0029], [@CIT0033]\] were missing appropriate data for pooling but reported statistically significant longer LOS in patients with CMV reactivation compared with those without reactivation (Cook et al \[[@CIT0009]\] mean 41 vs 19 days, Chiche et al \[[@CIT0010]\] median 27 vs 10 days, Heininger et al \[[@CIT0014]\] median 30 vs 12, von Müller et al \[[@CIT0026]\] median 42 vs 18 days, Chiche et al \[[@CIT0029]\] median 28 vs 14 days, and Heininger et al \[[@CIT0011]\] text only).

Hospital LOS was not different between those with and without CMV reactivation (4 studies, n = 343 patients, mean difference 5.21 days, 95% CI = −16.68--27.11; *P* = .6, I^2^ = 91%) but demonstrated substantial heterogeneity. Additional data that could not be pooled, however, reported statistically significant longer hospital LOS (Cook et al \[[@CIT0009]\] mean 55 vs 32 days and Heininger et al \[[@CIT0014]\] median 33 vs 16 days) in patients with CMV reactivation compared with those without reactivation.

DISCUSSION {#s13}
==========

This systematic review and meta-analysis of 22 studies demonstrates an association between CMV reactivation and ICU mortality, overall mortality, duration of mechanical ventilation, incidence of nosocomial infection, need for RRT, and ICU LOS in immunocompetent critically ill patients. To our knowledge, this is the first meta-analysis demonstrating an association not only between CMV reactivation and mortality, but also morbidity and health resource use. It is also the largest meta-analysis on this subject to date.

How CMV might alter patient prognosis in critical illness, however, still remains unclear. Some argue that CMV is a primary pathogen, whereas others believe it is simply a surrogate of disease severity---a bystander in the setting of critical illness. A number of hypotheses have been suggested to explain how CMV reactivation can be pathogenic. In addition to having direct cytopathic effect \[[@CIT0035]\], CMV infection can lead to the generation of inflammatory mediators, perpetuating the harmful proinflammatory/anti-inflammatory imbalance seen in critical illness \[[@CIT0036]\]. It has also been proposed that CMV has immunosuppressive effects---via its interference with antigen processing and impaired T-cell proliferation \[[@CIT0037]\].

Some authors have raised the possibility that CMV reactivation may simply be a marker of more severe illness \[[@CIT0040]\]. For example, patients with septic shock can develop a state of immunoparalysis, also called compensatory anti-inflammatory response syndrome \[[@CIT0031]\], that may increase the risk of CMV reactivation. Some have also suggested that immunoparalysis may be implicated in the increased risk of CMV reactivation associated with blood transfusion \[[@CIT0007], [@CIT0041]\], a phenomenon that often occurs in ICU. Moreover, bacterial infection may result in the release of endotoxin and tumor necrosis factor, which may also promote reactivation of latent CMV infection \[[@CIT0031]\]. Finally, infusion of exogenous catecholamines has been shown to encourage CMV reactivation \[[@CIT0031]\].

However, despite lacking data for pooling in many studies, our sensitivity analyses in patients with high versus low illness severity scores demonstrated similar associations between CMV and mortality. We do recognize that our analyses were subject to substantial heterogeneity given that we stratified using various severity scoring systems (APACHE II, SOFA, and SAPS II scores). Of interest, in studies that examined the interaction between CMV reactivation and severity of illness in adjusted analyses, severity of illness was not an independent predictor of CMV reactivation \[[@CIT0009], [@CIT0013], [@CIT0015], [@CIT0032]\]. In addition, in studies adjusting for severity of illness, CMV reactivation and mortality remained independently associated. Finally, some would argue that our included studies may suffer from time-dependent bias. Although such bias cannot be ruled out, it seems unlikely because CMV reactivation occurred relatively early in all studies.

Therefore, although the evidence is limited, the available data and plausible mechanisms described above suggest that CMV reactivation may be associated with higher mortality, and not simply correlated with disease severity. Further studies, specifically designed to test the associations between disease severity, CMV reactivation, and mortality in immunocompetent critically ill patients, are sorely needed.

The impact of CMV prophylaxis or preemptive therapy on outcomes in CMV- seropositive ICU patients remains to be determined. Epidemiological data have suggested a potential benefit \[[@CIT0042]\]. Randomized control trials are currently ongoing \[[@CIT0048], [@CIT0049]\]. The GRAIL (Study of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung and Respiratory Failure) study plans to examine the effect of antiviral prophylaxis on serum interleukin (IL)-6 levels, CMV reactivation, and mortality in immunocompetent mechanically ventilated ICU patients \[[@CIT0043]\]. The PTH (Preemptive Treatment for Herpesviridae) study will specifically examine the effect of preemptive treatment in ICU patients requiring prolonged mechanical ventilation (\>96 hours) \[[@CIT0049]\]. Outcomes will include ventilator-free days, mortality, and a number of other clinical outcomes \[[@CIT0044]\]. We hope these important studies will provide some much needed answers in the near future.

How CMV reactivation may result in longer durations of ventilation is also somewhat unclear. Evidence suggests the lungs may play an important role in the pathogenicity of CMV---as a major site of CMV latency \[[@CIT0045]\] and reactivation \[[@CIT0009], [@CIT0012]\]. Once reactivated, CMV infection can result in the release of pulmonary IL-11 \[[@CIT0046]\], secretion of fibrogenic cytokines, and the development of ARDS \[[@CIT0047], [@CIT0048]\]. This could potentially explain the longer duration of mechanical ventilation, as well as higher incidence of nosocomial pulmonary infection and longer lengths of stay, observed in patients with CMV reactivation in this systematic review.

The association between CMV reactivation and need for RRT is also of interest. To the best of our knowledge, it has never been reported. This association could be explained by the proinflammatory effect of CMV infection \[[@CIT0036]\]. Indeed, inflammatory cytokines have been implicated in the pathogenesis of sepsis-induced acute kidney injury \[[@CIT0049]\]. However, this hypothesis will have to be explored in further studies.

In terms of limitations, we found significant inconsistencies in data reporting across studies as shown in [Table 2](#T2){ref-type="table"}. For example, illness severity was inconsistently reported and, when available, was reported using a variety of severity scores, making it difficult to pool data. In addition, despite good quality reporting, only observational studies could be included because no randomized trials met eligibility. Therefore, our results are prone to bias and confounding based on study type alone.

Only few studies reported risk-adjusted outcomes, and, of those that did, most did not take into account important characteristics such as premorbid disease. Therefore, the risk of residual confounding in our analysis remains high. Few studies provided enough clinical characteristics of their study populations to perform meta-regression. In addition, attributable mortality was reported in only 1 study.

Some of our analyses demonstrated high heterogeneity likely due to the evolution of ICU care over time, different methods of CMV detection, the variability in performance of PCR assays, frequency of testing, and varied study populations. We did attempt to address this by conducting numerous sensitivity analyses. However, some studies reported data that was inappropriate for pooling. Of note, studies missing appropriate duration of mechanical ventilation or LOS data (means and standard deviations) reported similar outcomes as in our meta-analyses. Therefore, inclusion of these studies would have narrowed our CIs but would not have changed our final conclusions, with the exception of hospital LOS---where additional data might have resulted in statistical significance.

We also examined gray literature, which can be considered both a weakness (because this is not peer-reviewed data) and a strength (because it allowed us to reduce publication bias). Finally, one must consider that the distinction between CMV primary infection, reactivation, and disease is difficult without prior serostatus and/or tissue biopsy. Although CMV primary infection in ICU would be rare, as would CMV disease in immunocompetent patients, the possibility of misclassification bias cannot be excluded.

CONCLUSIONS {#s14}
===========

In conclusion, in this systematic review and meta-analysis, CMV reactivation was associated with increased ICU and overall mortality, prolonged mechanical ventilation, higher incidence of nosocomial infection, increased need for RRT, and prolonged ICU stay in immunocompetent critically ill patients. This evidence, despite various limitations, suggests that CMV reactivation may not simply be a marker of disease severity but may have a true pathogenic effect. In addition, the impact of CMV prophylaxis and/or preemptive therapy on outcomes in immunocompetent critically ill patients remains to be determined.

Supplementary Data {#s90}
==================

Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
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